Clinical Trial Update: PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

View source ↗

Summary

A clinical trial is evaluating whether a molecular signature response classifier can guide the choice among JAK inhibitors, T-cell inhibitors, or IL-6 inhibitor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)
• KEVZARA (sarilumab)
• ORENCIA (ABATACEPT)
• Olumiant (baricitinib)
• RINVOQ (Upadacitinib)
• XELJANZ (tofacitinib)

Snippet

Sponsor: Scipher Medicine | Conditions: Rheumatoid Arthritis | Status: RECRUITING